Caveolin-1 protects against liver injury and lipid accumulation in alcoholic fatty liver via ferroptosis resistance

  • 0Department of Pharmacy, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, Anhui, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China; Institute for Liver Diseases of Anhui Medical University, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China; Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China.

|

|

Summary

This summary is machine-generated.

Caveolin-1 (CAV1) protects against alcoholic fatty liver disease by inhibiting ferroptosis and lipid accumulation. Upregulating CAV1 shows therapeutic potential for treating alcoholic liver injury.

Area Of Science

  • Hepatology
  • Cell Biology
  • Biochemistry

Background

  • Alcoholic fatty liver (AFL) is a prevalent global liver disease with unclear pathogenesis.
  • Iron overload and lipid peroxidation are implicated risk factors in AFL development.
  • Caveolin-1 (CAV1) is known to regulate lipid homeostasis in non-alcoholic fatty liver.

Purpose Of The Study

  • To investigate the role of Caveolin-1 (CAV1) in ferroptosis within alcoholic fatty liver disease (AFL).
  • To explore CAV1 as a potential therapeutic target for AFL.

Main Methods

  • Established an AFL mouse model using chronic-plus-binge alcohol feeding.
  • Utilized in vitro AML-12 cells treated with ethanol and oleic acid.
  • Employed CAV1 scaffolding domain peptides (CSD) for CAV1 overexpression and small interfering RNA (siRNA) for knockdown.
  • Administered Erastin, a ferroptosis agonist, to assess its interaction with CAV1 effects.

Main Results

  • Alcohol-induced AFL triggered ferroptosis and reduced CAV1 expression in mice and cells.
  • CAV1 overexpression attenuated liver injury, hepatic steatosis, and ferroptosis in AFL models.
  • CAV1's protective effects on ferroptosis markers (SLC7A11, GPX4, ACSL4) and lipid accumulation were reversed by CAV1 siRNA.
  • Ferroptosis agonist Erastin counteracted CAV1's protective effects against ferroptosis and steatosis.

Conclusions

  • CAV1 plays a critical protective role against hepatic steatosis and ferroptosis in alcohol-induced liver injury.
  • Modulating CAV1 offers a potential therapeutic strategy for alcoholic fatty liver disease.